# Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

> **NCT04061239** · PHASE2 · RECRUITING · sponsor: **GWT-TUD GmbH** · enrollment: 150 (estimated)

## Conditions studied

- MDS
- AML

## Interventions

- **DRUG:** CPX-351
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04061239
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-19
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061239, "Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04061239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*